Abstract
962P SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have